By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PARI Pharma 

Steinerstrasse 15A

Munich    D-81369  Germany
Phone: 49-89-742-84669 Fax: 49-89-742-84650



Company News
PARI Pharma Development Featuring eFlow Technology for Bronchiolitis Obliterans Syndrome (BOS) Is Licensed To Breath Therapeutics Holding BV 3/20/2017 11:15:14 AM
Breath Therapeutics Holding BV Spins Out of PARI Pharma With $46 Million and a Ready-to-Go Phase III Drug/Device Combo 3/8/2017 5:42:42 AM
PARI Pharma's Investigational Closed eFlow Nebulizer System Used In Two Successful Phase 3 Clinical Studies Evaluating Sunovion Pharmaceuticals Inc.'s SUN-101 (Glycopyrrolate) In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 6/7/2016 8:28:06 AM
Polyphor Develops The Elastase Inhibitor POL6014 For Rare Lung Diseases Using PARI Pharma’s Eflow Technology Inhalation Device 1/9/2015 7:53:56 AM
PARI Pharma's Altera Delivers Gilead Sciences, Inc. (GILD)'s Cayston in Head-to-Head Study With Tobramycin Inhalation Solution 6/21/2010 11:08:20 AM
PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA 2/11/2010 10:29:56 AM
PARI Pharma's Altera Delivers Gilead Sciences, Inc. (GILD)'s Cayston, Approved by European Commission to Treat Cystic Fibrosis 9/24/2009 8:45:06 AM
Mpex Pharmaceuticals, Inc. Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma's eFlow Technology 9/15/2009 7:59:58 AM
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans 6/3/2009 8:24:14 AM
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS 5/21/2009 10:48:34 AM